T cell receptor on type II collagen-specific T cell (TCR (type II collagen-specific))

The **T cell receptor (TCR) on type II collagen-specific T cells** is a heterodimeric transmembrane receptor expressed by T lymphocytes that recognize peptides derived from type II collagen presented by MHC class II molecules, mainly in the context of autoimmune disease models such as collagen-induced arthritis (CIA)[1][3]. These TCRs are typically restricted to recognition of specific immunodominant epitopes of type II collagen (notably CII 256-270), and their engagement initiates T cell activation, cytokine secretion, and provision of help to B cells. In susceptible animal models, a highly restricted set of TCR alpha and beta chains mediate autoimmunity against type II collagen, contributing to disease pathology analogous to human rheumatoid arthritis[1][3]. Suppression or selective depletion of these TCRs reduces disease incidence and severity in murine models, making this TCR population a central node in experimental autoimmunity and a potential therapeutic target for intervention in analogous human diseases[1][3]. There are currently no approved therapies that directly target this receptor in humans; most interventions are through broad immunosuppression.

Other names

T cell receptor of type II collagen-specific T cellCollagen type II-specific TCRCII-specific T cell receptorCollagen II T cell receptor

Depleting or modulating TCR Vβ8.2 clonal families with monoclonal antibodies reduces pathogenic T cell responses and disease severity in collagen-induced arthritis models. General TCR antagonism or immunosuppression blocks antigen recognition and downstream immune activation.